For some patients Yondelis is almost a miracle. "Dr. Robert Maki, an oncologist at Memorial Sloan Kettering Cancer Center in New York and an expert in sarcoma, is unequivocal in his opinion on the ET-743 ...
"There is a percentage of patients on regular medication which had not achieved anything and they are alive thanks to him, "he says. For Maki, now the challenge is to know why Yondelis is definitive in some sarcomas, whereas in others the response is much less clear. "These tumors are very heterogeneous and that forces us to know the molecular signature of each of them. We must learn to treat them according to their gene expression to target therapeutically better than we do now, "he adds. Their concern is whether it will continue to treat patients who have responded to the product of PharmaMar.
Experts insist that anti-cancer has a great profile that goes beyond sarcomas. Andrés Poveda, the Valencian Institute of Oncology, highlights its effectiveness in ovarian tumors. The medical community knows the product is convinced that he has a clear anti-tumor activity, with few side effects, and oncologic applications can be so diverse that, sooner or later, hit the market.
